CNS Pharmaceuticals Statistics
Share Statistics
CNS Pharmaceuticals has 2.94M
shares outstanding. The number of shares has increased by 0.2%
in one year.
| Shares Outstanding | 2.94M |
| Shares Change (YoY) | 0.2% |
| Shares Change (QoQ) | 30.66% |
| Owned by Institutions (%) | 3.2% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | n/a |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 323.81K, so 11% of the outstanding
shares have been sold short.
| Short Interest | 323.81K |
| Short % of Shares Out | 11% |
| Short % of Float | 11% |
| Short Ratio (days to cover) | 1.27 |
Valuation Ratios
The PE ratio is -0.15 and the forward
PE ratio is -0.24.
CNS Pharmaceuticals's PEG ratio is
0.
| PE Ratio | -0.15 |
| Forward PE | -0.24 |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 0.37 |
| P/FCF Ratio | -0.13 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for CNS Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.43,
with a Debt / Equity ratio of 0.05.
| Current Ratio | 3.43 |
| Quick Ratio | 3.43 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.02 |
| Interest Coverage | 924.44 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-3,714,450.25 |
| Employee Count | 4 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by null% in the
last 52 weeks. The beta is 1.08, so CNS Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 1.08 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 1.94 |
| 200-Day Moving Average | 7.82 |
| Relative Strength Index (RSI) | 38.57 |
| Average Volume (20 Days) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -14.9M |
| Net Income | -14.86M |
| EBITDA | -14.9M |
| EBIT | -14.87M |
| Earnings Per Share (EPS) | -38.87 |
Full Income StatementBalance Sheet
The company has 6.46M in cash and 326.07K in
debt, giving a net cash position of 6.14M.
| Cash & Cash Equivalents | 6.46M |
| Total Debt | 326.07K |
| Net Cash | 6.14M |
| Retained Earnings | -84.42M |
| Total Assets | 8.7M |
| Working Capital | 6.13M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -17.11M
and capital expenditures -4.19K, giving a free cash flow of -17.12M.
| Operating Cash Flow | -17.11M |
| Capital Expenditures | -4.19K |
| Free Cash Flow | -17.12M |
| FCF Per Share | -44.78 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
